KR100484883B1 - 바이러스성입자를생산하는캡슐화세포 - Google Patents

바이러스성입자를생산하는캡슐화세포 Download PDF

Info

Publication number
KR100484883B1
KR100484883B1 KR1019970709807A KR19970709807A KR100484883B1 KR 100484883 B1 KR100484883 B1 KR 100484883B1 KR 1019970709807 A KR1019970709807 A KR 1019970709807A KR 19970709807 A KR19970709807 A KR 19970709807A KR 100484883 B1 KR100484883 B1 KR 100484883B1
Authority
KR
South Korea
Prior art keywords
cells
cell
sulfate
capsule
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019970709807A
Other languages
English (en)
Korean (ko)
Other versions
KR19990028491A (ko
Inventor
로버트 미샤엘 잘러
발터 하. 귄즈부룩
브리안 잘몬스
Original Assignee
버베리안 노딕 에이/에스
게에스에프 포르슝스젠트룸 퓌르 움벨트 운트 게준드하이트게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100484883(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 버베리안 노딕 에이/에스, 게에스에프 포르슝스젠트룸 퓌르 움벨트 운트 게준드하이트게엠베하 filed Critical 버베리안 노딕 에이/에스
Publication of KR19990028491A publication Critical patent/KR19990028491A/ko
Application granted granted Critical
Publication of KR100484883B1 publication Critical patent/KR100484883B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
KR1019970709807A 1995-06-27 1996-06-24 바이러스성입자를생산하는캡슐화세포 Expired - Lifetime KR100484883B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK0740/95 1995-06-27
DK74095 1995-06-27
DK740/95 1995-06-27

Publications (2)

Publication Number Publication Date
KR19990028491A KR19990028491A (ko) 1999-04-15
KR100484883B1 true KR100484883B1 (ko) 2005-09-02

Family

ID=8097001

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970709807A Expired - Lifetime KR100484883B1 (ko) 1995-06-27 1996-06-24 바이러스성입자를생산하는캡슐화세포

Country Status (21)

Country Link
US (1) US6776985B1 (cg-RX-API-DMAC7.html)
EP (1) EP0835137B1 (cg-RX-API-DMAC7.html)
JP (2) JP4119952B2 (cg-RX-API-DMAC7.html)
KR (1) KR100484883B1 (cg-RX-API-DMAC7.html)
CN (1) CN1187095C (cg-RX-API-DMAC7.html)
AT (1) ATE309000T1 (cg-RX-API-DMAC7.html)
AU (1) AU708273B2 (cg-RX-API-DMAC7.html)
CA (1) CA2222559A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ286979B6 (cg-RX-API-DMAC7.html)
DE (1) DE69633180D1 (cg-RX-API-DMAC7.html)
DK (1) DK0835137T3 (cg-RX-API-DMAC7.html)
ES (1) ES2253754T3 (cg-RX-API-DMAC7.html)
IL (1) IL122119A (cg-RX-API-DMAC7.html)
NO (1) NO321427B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ312671A (cg-RX-API-DMAC7.html)
PL (1) PL185338B1 (cg-RX-API-DMAC7.html)
PT (1) PT835137E (cg-RX-API-DMAC7.html)
RU (1) RU2187301C2 (cg-RX-API-DMAC7.html)
SI (1) SI0835137T1 (cg-RX-API-DMAC7.html)
UA (1) UA65525C2 (cg-RX-API-DMAC7.html)
WO (1) WO1997001357A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3908274B2 (ja) 1995-03-09 2007-04-25 ゲーエスエフ−フォルシュンクスツェントラム・フュア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー 遺伝子治療用の抗菌ペプチドをコードする治療用遺伝子を有するベクター
ATE309000T1 (de) 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
RU2185821C2 (ru) 1996-03-27 2002-07-27 Бавариан Нордик Рисерч Инститьют А/С Трансдуцирующие цитохром р450 ретровирусные векторы
WO1999056660A1 (en) 1998-05-05 1999-11-11 Koninklijke Philips Electronics N.V. Toothbrush comprising a brush member having a bristle field and an interdental bristle field
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
JP2008540347A (ja) 2005-05-03 2008-11-20 フェテリネールメディツィニシュ ウニベルジテート ウィーン 浸透性カプセル
CN101903049B (zh) 2007-12-20 2014-08-13 伊西康公司 包囊的肾组织
KR101250925B1 (ko) * 2011-10-28 2013-04-04 한화케미칼 주식회사 캡슐 세포용 구조체
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
FR3044016A1 (fr) * 2015-11-24 2017-05-26 Glaxosmithkline Ip Dev Ltd Lignees cellulaires stables pour la production retrovirale
KR102067352B1 (ko) * 2015-11-24 2020-01-16 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 레트로바이러스 생산을 위한 일시적인 형질감염 방법
US11427809B2 (en) 2016-05-25 2022-08-30 Lonza Houston, Inc. Methods for isolating adeno-associated virus using a polydialkylammonium salt
RU2688383C2 (ru) * 2017-07-10 2019-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Способ синтеза белка в культуре бактериальных клеток
CA3220737A1 (en) * 2021-05-21 2022-11-24 Bionaut Labs Ltd. System and method for localized therapeutic treatment
CN115820683B (zh) * 2022-09-28 2024-04-05 西南大学 家蚕Cyp9a20基因及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
EP0476953A2 (en) * 1990-09-14 1992-03-25 The General Hospital Corporation Viral targeted destruction of neoplastic cells
WO1992010564A1 (en) * 1990-12-13 1992-06-25 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD160393A3 (de) * 1980-11-14 1983-07-27 Horst Dautzenberg Mikrokapseln und verfahren zu ihrer herstellung
US4686098A (en) * 1984-05-14 1987-08-11 Merck & Co., Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
EP0199362A3 (en) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology System and apparatus for delayed and pulsed release of biologically active substances
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
WO1989011539A1 (en) 1988-05-17 1989-11-30 Sloan-Kettering Institute For Cancer Research Retroviral vector
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE4021050A1 (de) * 1990-06-29 1992-01-02 Akad Wissenschaften Ddr Verfahren zur herstellung von mikrokapseln
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
CA2198210C (en) 1994-09-02 2006-07-11 Gsf - Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Non self-inactivating, expression targeted retroviral vectors
ATE309000T1 (de) 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
DK0848757T3 (da) 1995-09-06 2002-07-01 Austrian Nordic Biotherapeutic Anvendelse af WAP eller MMTV regulatoriske sekvenser for målrettet ekspression af sammenkædede heterologe gener i humane mammae celler, inklusiv humane mammae carcinoma celler
RU2185821C2 (ru) 1996-03-27 2002-07-27 Бавариан Нордик Рисерч Инститьют А/С Трансдуцирующие цитохром р450 ретровирусные векторы

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
EP0476953A2 (en) * 1990-09-14 1992-03-25 The General Hospital Corporation Viral targeted destruction of neoplastic cells
WO1992010564A1 (en) * 1990-12-13 1992-06-25 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antiviral Research, 제10권, 제179면 내지 제191면(1988) *

Also Published As

Publication number Publication date
PL185338B1 (pl) 2003-04-30
EP0835137B1 (en) 2005-11-09
AU6415496A (en) 1997-01-30
IL122119A (en) 2004-06-01
ES2253754T3 (es) 2006-06-01
KR19990028491A (ko) 1999-04-15
NZ312671A (en) 1999-10-28
DK0835137T3 (da) 2006-03-06
CZ419597A3 (cs) 1998-03-18
CZ286979B6 (en) 2000-08-16
RU2187301C2 (ru) 2002-08-20
HK1010139A1 (en) 1999-06-17
JPH11508768A (ja) 1999-08-03
AU708273B2 (en) 1999-07-29
CN1187095C (zh) 2005-02-02
DE69633180D1 (de) 2004-09-23
PT835137E (pt) 2004-12-31
NO321427B1 (no) 2006-05-08
JP2008101011A (ja) 2008-05-01
EP0835137A1 (en) 1998-04-15
NO975813L (no) 1998-02-23
JP4848348B2 (ja) 2011-12-28
UA65525C2 (en) 2004-04-15
JP4119952B2 (ja) 2008-07-16
US6776985B1 (en) 2004-08-17
IL122119A0 (en) 1998-04-05
SI0835137T1 (sl) 2006-04-30
CA2222559A1 (en) 1997-01-16
PL324289A1 (en) 1998-05-11
NO975813D0 (no) 1997-12-10
WO1997001357A1 (en) 1997-01-16
ATE309000T1 (de) 2005-11-15
CN1189104A (zh) 1998-07-29

Similar Documents

Publication Publication Date Title
JP4848348B2 (ja) ウイルス粒子産生カプセル化細胞
US6027721A (en) Device and method for encapsulated gene therapy
EP2673001B1 (en) Nts-polyplex nanoparticles system for gene therapy of cancer
JP2703893B2 (ja) 外来遺伝子物質を発現する上皮細胞
US6893634B1 (en) Encapsulated cells producing cytochrome P450
DE69619683T2 (de) Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
JP3535521B2 (ja) レトロウイルスベクターおよび遺伝子治療におけるその用途
DE69732710T2 (de) Mononukleare phagozyten zur verabreichung von therapeutischen arzneimitteln
AU724537C (en) Method for gene transfer to the central nervous system
CN119367318B (zh) 一种递送生物正交型pdl1降解剂的声相变纳米液滴及其制备方法和应用
JPH11509735A (ja) 遺伝子導入、遺伝子治療及びタンパク質合成のための陽性選択マーカーとしてのシチジンデアミナーゼcDNA
US6540995B1 (en) Encapsulated cells producing cytochrome P450
HK1010139B (en) Encapsulated cells producing viral particles
Armeanu et al. In vivo perivascular implantation of encapsulated packaging cells for prolonged retroviral gene transfer
D’INHIBITEURS et al. ANTISENSE SDI-1 NUCLEOTIDE SEQUENCES
Vile et al. Retroviral Vectors From Laboratory Tools to Molecular Medicines
HK1034283B (en) Use of triplex structure dna sequences for transferring nucleotide sequences

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19971227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20001206

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20010622

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20021213

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20030729

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040128

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040904

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20050307

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20050413

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20050414

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20080326

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20090407

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20100406

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20110405

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20120405

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20130326

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20130326

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20140326

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20140326

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20160324

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20160324

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20161224

Termination category: Expiration of duration